Suppr超能文献

2019 年 9 月至 10 月,希腊爆发了产 KPC-2 的肺炎克雷伯菌,该菌对头孢他啶-阿维巴坦具有耐药性,是通过 VEB-1 突变体(VEB-25)介导的。

Outbreak of KPC-2-producing endowed with ceftazidime-avibactam resistance mediated through a VEB-1-mutant (VEB-25), Greece, September to October 2019.

机构信息

Infectious Diseases Laboratory, 4th Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.

1st Internal Medicine & Infectious Diseases Department, Hygeia General Hospital, Athens, Greece.

出版信息

Euro Surveill. 2020 Jan;25(3). doi: 10.2807/1560-7917.ES.2020.25.3.2000028.

Abstract

From September to October 2019, seven patients colonised or infected with a ceftazidime-avibactam (CZA)-resistant carbapenemase (KPC)-2-producing were detected in two intensive care units of a Greek general hospital. The outbreak strain was sequence type (ST)147 and co-produced KPC-2 and the novel plasmid-borne Vietnamese extended-spectrum β-lactamase (VEB)-25 harbouring a K234R substitution associated with CZA resistance. Epidemiological investigations revealed that the resistance was probably acquired by horizontal transmission independently from previous CZA exposure.

摘要

2019 年 9 月至 10 月,在希腊一家综合医院的两个重症监护病房中,检测到 7 例定植或感染产头孢他啶-阿维巴坦(CZA)耐药碳青霉烯酶(KPC)-2 的患者。暴发菌株为序列型(ST)147,同时产生 KPC-2 和新型质粒介导的越南超广谱β-内酰胺酶(VEB)-25,该酶携带与 CZA 耐药相关的 K234R 取代。流行病学调查显示,耐药性可能是通过水平传播获得的,与之前的 CZA 暴露无关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ca6/6988274/f4d099e271c2/2000028-f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验